Colorectal Cancer (CRC) Screening in the Geriatric Population: Factors in Risk Assessment and Outcome Benefits

by C. S. Pitchumoni, Shivani Sharma

INTRODUCTION

In our previous articles in this series we have emphasized the growing number of elderly in the USA, bringing to light the importance of identifying measures to keep the older adults healthy, vigorous and disability free (1). Indeed the older adults today are living longer, and healthier because of the many successful measures taken in the past three decades. One of the very successful measures that have been acclaimed is colorectal cancer (CRC) screening (2,3). Lifetime risk of developing CRC in the USA is one in 17, the risk alike in men and women, with 90% of the cases occurring beyond age 50 years. Overall five-year survival rates have improved during the past two decades; from 50% to 60% (4). Implementing CRC screening in eligible individuals has excellent effectiveness clinically and economically. CRC screening is the search for polyps and cancer in individuals who have not been previously diagnosed with colonic neoplasms, and surveillance implies follow-up of patients who have had the diagnosis of colonic neoplasms. Diagnostic examinations are different from screening and surveillance and are performed to evaluate a patient with symptoms indicative of colonic neoplasms.

Many randomized controlled studies have clearly shown that screening colonoscopy for colorectal cancer reduces mortality by recognition of polyps and cancer in earlier stages (by Duke’s classification) (2,5–9). However, these observations are not specific to the older adults, since most studies group all individuals over 65 years of age in one group, with no subgroups.

In this review we have briefly addressed the current status of CRC screening followed by our analysis on the recent controversies in discontinuing screening colonoscopy after a certain age. Obviously, discontinuing arbitrarily a well accepted procedure such as screening colonoscopy based solely on the chronological age can neither be too early—which will limit the value of a proven technique in reducing CRC related deaths—nor too late in advanced age (with a lower life expectancy) when the risks of colonoscopy begin to outweigh the benefits. Many debates on screening colonoscopy in older adults are also prompted by a desire to free up endoscopic resources to screen younger individuals with a longer life expectancy. The demand for screening colonoscopy continues to strain the USA health care system despite overall low participation rates (10).

Epidemiology of CRC in different population groups is presented here to provide another facet in the controversy in order to understand the relative importance of the incidence of the disease. The aim certainly is not to exclude any ethnic or racial group from screen-
ing, but the need to intensify screening in certain groups such as African Americans and solely to provide an idea about the relative risks in different ethnic groups. For example, a 75-years-old Asian Indian who has recently migrated to the USA certainly has a lower risk for colon cancer as compared to an African American or a Caucasian of the same age in the USA. Important differences in the data on screening colonoscopies in different ethnic groups may help us to justify customization of the screening recommendations based on race and ethnicity (11). And this appears to be a need in view of the current limited capacity that constrains our ability to meaningfully improve CRC screening rates (10).

**EPIDEMIOLOGY OF COLORECTAL CANCER IN RELATION TO AGE/RACE/ETHNICITY**

An understanding of the incidence of CRC risk based on race, gender, and age may help us to assess risk and justify customizations of screening recommendations. In the USA, where there is a “melting pot” or “salad bowl” of different ethnic groups, CRC screening recommendations are already complex. Many may object to adding another layer of complexity based on race or ethnicity or any one of the other factors to the general recommendations which might add a new barrier, perhaps even reducing the overall efficiency of screening programs (12). National guidelines of CRC screening are the same for all ethnic groups in the USA and at this time certainly do not exclude Asians, Indians, or others based on a lower incidence of CRC (6,13).

**Epidemiology of CRC in the USA**

CRC continues to be the number one cause of GI related mortality and is the second leading cause of cancer-related deaths in the USA (14). While SEER (Surveillance, Epidemiology, and End Results Program) (http://seer.cancer.gov) data demonstrates modest decreases in both the incidence and mortality rates, CRC dwarfs all the other GI malignancies both in incidence and in mortality in the USA (15).

Approximately 148,610 new cases of CRC are diagnosed each year, of which 106,680 are colon and the remainder rectal cancers. In 2006, more than 55,000 Americans were expected to die of CRC, accounting for approximately 10% of all cancer deaths (16).

**Effect of Age**

CRC is a rare diagnosis before the age of 40, the incidence begins to increase significantly between the ages of 40 and 50, and age-specific incidence rates increase progressively thereafter to 3.7/1000 per year by age 80 (15). The incidence of CRC approximately doubles during each successive decade from age 40–80 years (17) This is well illustrated in Figure 1.

A progressive increase in the frequency of advanced CRC occurs with age. The risk of having advanced colonic lesions increases by 1.05-fold for every single-year increase in age. A 4-fold increase in prevalence of advanced colonic neoplasm is seen in patients more than 70 years old compared with those less than 50 years of age (18). Hence, the older the patient the greater the likelihood of a benefit from CRC screening procedures, not considering other conflicting factors discussed.

**Prevalence of CRC in Different Groups**

The USA is a country of immigrants and the prevalence of CRC in immigrants from different parts of the world is useful information for practitioners of medicine in major metropolitan areas. The following is an analysis of epidemiologic observations on the differences in the incidence of CRC based on data from different coun-

(continued on page 21)
tries and ethnic groups. Globally, the incidence of CRC varies 10-fold, with the highest incidence rates in North America, Australia, and northern and western Europe; developing countries have lower rates, particularly Africa and Asia. These geographic differences appear to be attributable to differences in dietary and environmental exposures that are imposed upon a background of genetically determined susceptibility (19). We recognize that in many ethnic groups (as in the Japanese) that migrated to the USA decades ago, the incidence of CRC has increased and matches the USA population figures. Similarly, a rapid change in CRC epidemiology is noted in some Asian countries making the data subject to careful and constant scrutiny.

CRC in Caucasians and African Americans

The United States has one of the lowest mortality rates from CRC, despite having a higher incidence than most countries. Data collected by the SEER suggest that 61% of all patients treated for colorectal cancer (all stages and sites combined) survive five years (20). In contrast, the lowest five-year survival rates have been reported by China and Eastern Europe (32% and 30%, respectively) (19).

Based on the most recent data from 1997 to 2001, the age-adjusted incidence of CRC (more likely to be diagnosed with CRC) per 100,000 individuals was 63 for African Americans versus 53.3 for whites, representing a 19% higher incidence rate. The age-adjusted mortality rate (more likely to die from CRC) over the same period was 28.3 for African Americans versus 20.3 for whites representing a 39% higher mortality rate. Translating these rates into 5-year survival numbers reveals that African-American men with CRC have a 5-year survival of 51% compared with 59% for white men. A similar trend is seen for women (21).

In addition to presenting at more advanced stages of disease, African Americans also present at a slightly younger age with CRC. Among the over three million cases of CRC in the National Cancer Database between 1985 and 1993, African Americans presented at an average age of 66.4 versus 69.7 for whites. Table 1 shows the incidence and mortality rates by age and race based on SEER data from 1997 to 2001. Both incidence and mortality increase with age. The disparity between African Americans and whites also exists among all the age cohorts studied; however, it seems most pronounced for the youngest cohorts. A younger age at onset with greater differences in mortality rates among the younger cohorts raises the question of the role of genetic and lifestyle factors in contributing to the differences (21).

An unexplored field is the need to intensify screening of the healthy older African American in the USA.

CRC in Asians

The incidence of CRC in Asians in their home countries may be lower than in western countries (22). Although it is generally believed that CRC is more prevalent in Western countries, there has been a rapid rise over the past few decades in CRC incidences in a few countries.
in Asia (23). A comparison of the CRC incidence rates in Japan and the United States has shown a dramatic rise in Japanese rates (22–25). According to the South Korea National Statistical Office, there was a 35% increase in CRC mortality in Korea over the past two decades. In China the data also suggest that the CRC incidence is rising in some urban areas, e.g., Shanghai. The incidence of CRC in Chinese men in Hong Kong has increased from 30 per 100,000 in 1984 to 55 per 100,000 in 2002. The age-standardized incidence rates of CRC in some Asian countries are now comparable with that of Western figures (18,26–28).

CRC ranks number three among the incidence of cancers and one of the three most rapidly increasing cancers in China (28). For reasons unclear the Chinese seem to have a higher risk for developing CRC compared to Malaysians and Indians (29). Further, Chinese patients tend to have the majority of their (65%–71%) cancers in the distal colon (30,31). This increases the yield for screening sigmoidoscopy. There is less advantage of colonoscopy over sigmoidoscopy as a screening tool for CRC in the Chinese compared to American (32). Certainly the alarming increase in the incidence of CRC in China cautions us not to ignore the Chinese population from CRC screening.

The crude prevalence of all colonic neoplasms was highest among Japanese (42.3%) and lowest among Indian patients (8.5%) (18). CRC in Indians appears to be relatively low compared to Westerners and Chinese and Japanese. Large scale migration to the USA from India occurred only in the last three decades. No study has been conducted on the incidence of CRC in Indian immigrants in the USA. It is not known whether the low incidence in India continues to be a feature in Indians in the USA after decades of immigration and in Asian Indians born in the USA. Excluding any ethnic group residing long term in the USA from CRC screening based on epidemiologic data may not be a good practice of medicine in the USA, in a society that is highly litigious, and considering the long term influence of environmental factors or life style changes in the USA.

CURRENT RECOMMENDATIONS FOR CRC SCREENING

The following is a summary of currently accepted guidelines in CRC screening. Current recommenda-

Risk Stratification

Clinicians should determine an individual patient’s risk status well before initiation of screening. The individual’s risk status determines when screening should be initiated and what tests and frequency are appropriate.

Risk stratification is accomplished by asking several questions aimed at uncovering the risk factors for CRC (13):

• Has the patient had CRC or an adenomatous polyp?
• Does the patient have an illness (e.g., inflammatory bowel disease) that predisposes him or her to CRC?
• Has a family member had CRC or an adenomatous polyp? If so, how many, was it in a first degree relative (parent, sibling, or child), and at what age was the cancer or polyp first diagnosed?
• Does the family history suggest one of the genetic syndromes (familial adenomatous polyposis or hereditary non-polyposis colorectal cancer)?

A positive response to any of these questions should prompt further efforts to identify and define the specific condition associated with increased risk.

Recommendations for the Average Risk Population

According to current recommendations average risk individuals should be offered options for screening for CRC at the age of 50 years. These updated 2003 options include FOBT annually without slide rehydra-
tion, flexible sigmoidoscopy every five years, combined FOBT and sigmoidoscopy, colonoscopy every 10 years, or Double Contrast Barium Enema (DCBE) every five years (33). These recommendations differ slightly from organization to organization and are constantly updated. We have compared the relative merits and weaknesses of the options in Table 2.

**Recommendations for Men and Women at Increased Risk of CRC**

According to the current data, recommendations should be individualized for above-average risk persons. Decision should be tailored to the individual’s level of risk based on the personal, family and medical history. A complete visualization of the colon should be advised if the results are abnormal. Colonoscopy is the preferred test for abnormal results but some physicians may recommend flexible sigmoidoscopy with DCBE in case colonoscopy is unavailable. Usually one positive FOBT out of six samples is considered to be positive screening test and should be followed by diagnostic colonoscopy (33).

**CURRENT OPTIONS ARE SUMMARIZED BASED ON NEWER DATA**

**FOBT**

In a recent issue of the *American Journal of Gastroenterology* the current status of FOBT in CRC screening was discussed in an editorial as well as in three articles one each from the UK, China and the USA. Although the USA has accepted colonoscopy as the mainstay in screening, the above articles reemphasized the role of FOBT for its simplicity, cost and reliability, although much limited. In many other countries colonoscopy is considered impractical, costly, and perhaps even an unwanted risk (34). Sung, from China, noted a point relevant to this article; he pointed out that FOBT remains the most affordable test, with good evidence for life saving and the most likely accepted method of screening. Further, because of the enormous aging population and minimally subsidized health care system, FOBT is the only viable option for that country for a long time to come (35). FOBT despite its simplicity is noted to reduce CRC mortality by 33% in the USA (36). FOBT which is considered by all the three countries (UK, China, and the USA) a viable screening strategy may surprise many readers in the USA who consider colonoscopy as the only option.

Adequate performance of FOBT requires that the patient avoid red meat and peroxidase-rich foods (broccoli, turnips, cantaloupe, cauliflower, radishes), and certain medications such as vitamin C, aspirin, and NSAIDS for three days prior to and during testing. Slides should be developed within four-to-six days. Hydration of the slide by adding a drop of water increases sensitivity but increases false positivity and may lead to many more avoidable colonoscopic examinations.

It is also of interest to note that FOBT is the only screening option that has been shown in randomized controlled trials to reduce both the mortality and the incidence of CRC. Evidence based CRC screening guidelines in the USA include annual FOBT either alone or in combination with flexible sigmoidoscopy as an acceptable screening option (6,13,37). Even in the USA, an affluent country, neither the resources nor the capacity exists to perform general population based colonoscopy screening (36,38).

**Sigmoidoscopy**

Selby, et al and Newcomb, et al in two separate studies concluded that there is a definite reduction in the distal CRC mortality with screening sigmoidoscopy (2,39). On the contrary, there are studies which highlight a major limitation of flexible sigmoidoscopy, i.e. the inability to visualize the right side of the colon. A case control study by Rex, et al reported that at least 30% of patients with high grade CRC have disease proximal to the splenic flexure with no signs of disease distal to the splenic flexure and can be expected to have a negative flexible sigmoidoscopy (40). Similar findings were reported by Imperiale, et al and Lieberman, et al in separate case control studies (41,42).

Regardless of the limitations, flexible sigmoidoscopy is used in many centers in conjunction with FOBT as a primary screening measure for CRC. Perhaps something is better than nothing, when it comes to a question of mass screening for CRC. Data indi-
cates that in the older adults the yield of sigmoidoscopy may be less as compared to young individuals. Older age increases the absolute risk of advanced neoplasia in the right half of the colon (5.6% in >65 years versus 0.8% in the group aged 50–54 years) decreasing the sensitivity of sigmoidoscopy which only helps to exclude left sided lesions (43–45).

**Colonoscopy**

Screening colonoscopy is considered the best option for CRC screening although there are no randomized controlled studies. Colonoscopy is the only method for total colonic evaluation, detection of early cancers by biopsy, detection and resection of polyps. The questions which are posed on the feasibility of mass screening are based on the cost, risk, compliance, and finally the capacity of the medical system. Certainly most countries other than the USA do recognize the superiority of colonoscopy, but have not followed the recommendations in the USA. Seeff and colleagues rightly pointed out the colonoscopy capacity even in the USA is seriously limited and other screening strategies are needed to reach the estimated 41.8 mil-

---

**Table 2. Screening Strategies for CRC**

<table>
<thead>
<tr>
<th>Test</th>
<th>Advantage</th>
<th>Disadvantage</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Traditional Options</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FOBT</td>
<td>Inexpensive</td>
<td>Low sensitivity/ specificity</td>
</tr>
<tr>
<td></td>
<td>Good compliance</td>
<td>Bleeding from upper GI tract may create a dilemma.</td>
</tr>
<tr>
<td></td>
<td>Noted to reduce mortality from CRC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detects lesions in the entire colon</td>
<td></td>
</tr>
<tr>
<td>Flexible Sigmoidoscopy</td>
<td>Low cost</td>
<td>Proximal lesions are missed</td>
</tr>
<tr>
<td></td>
<td>Shown to reduce disease/death from left sided</td>
<td>Not ideal for polypectomy</td>
</tr>
<tr>
<td></td>
<td>cancers</td>
<td>Since no sedation is given, often uncomfortable</td>
</tr>
<tr>
<td></td>
<td>Biopsy is feasible</td>
<td></td>
</tr>
<tr>
<td>Double contrast barium enema</td>
<td>Moderate cost</td>
<td>Low sensitivity</td>
</tr>
<tr>
<td></td>
<td>Detects polyps &gt;1 cm</td>
<td>Biopsy not feasible</td>
</tr>
<tr>
<td></td>
<td>Low complications</td>
<td>Colonoscopy is indicated if a lesion is found</td>
</tr>
<tr>
<td></td>
<td></td>
<td>No study has shown reduction in mortality</td>
</tr>
<tr>
<td>Colonoscopy</td>
<td>Entire colon is visualized</td>
<td>Expensive</td>
</tr>
<tr>
<td></td>
<td>Polypectomy/ biopsy is feasible</td>
<td>Patient compliance may be poor</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Risks for perforation, bleeding, sedation associated risks</td>
</tr>
<tr>
<td><strong>Newer Options</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Virtual Colonoscopy</td>
<td>Good sensitivity for polyps &gt;1 cm</td>
<td>Expensive</td>
</tr>
<tr>
<td></td>
<td>Low risk of perforation</td>
<td>Poor results for small polyps</td>
</tr>
<tr>
<td></td>
<td>Can be followed by traditional colonoscopy if</td>
<td>Requires bowel preparation</td>
</tr>
<tr>
<td></td>
<td>positive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Detection of extra colonic findings (e.g.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>aortic aneurysms</td>
<td></td>
</tr>
<tr>
<td>PillCam Colonoscopy</td>
<td>Increased patient acceptability</td>
<td>Requires bowel preparation</td>
</tr>
<tr>
<td></td>
<td>Good sensitivity/ specificity in early studies</td>
<td>No therapeutic options</td>
</tr>
</tbody>
</table>
lion people above age 50 years, who have not been screened for CRC (46). The risks of colonoscopy, albeit small, and other issues are discussed subsequently in relation to its application in the elderly.

**Double Contrast Barium Enema (DCBE)**

The national guidelines in CRC screening recommend DCBE once in five years as an acceptable substitute for colonoscopy (47). There are no randomized trials evaluating whether screening with DCBE reduces the incidence or mortality from CRC.

In three separate studies Winawer, et al, Rex, et al, and Rockey, et al reported the sensitivity and specificity of DCBE to be very low as compared to screening colonoscopy (47–49).

**VIRTUAL COLONOSCOPY**

**Virtual Colonoscopy (VC)**

Virtual colonoscopy (VC) known as CT colonography has shown mixed results. In the Pickhardt trial 50 VC showed excellent results, not demonstrated in two other studies (49,51). The American College of Radiology Imaging Network’s (ACRIN) national trial to be published is expected to offer useful data.

VC and Capsule Colonoscopy, if shown to be sensitive enough to detect polyps are likely to be preferred by many as screening procedures. However, most of the patients who have undergone colonoscopy dislike the ritual of colon preparation the day before more than the procedure itself. Most patients requiring VC require the same preparation that traditional colonoscopy demands. The success rates on polyp detection are quiet variable (52–54). A significant improvement for VC would be effective polyp detection without bowl preparation (55–57).

**THE FUTURE ALTERNATIVES TO TRADITIONAL COLONOSCOPY**

It is estimated that currently there are more than 40 million adults over the age of 50 who have never been screened for colon cancer. Newer options to traditional colonoscopy might improve compliance if they are less invasive, less time consuming and less expensive and associated with no complications.

**Stool DNA Tests for Colon Cancer**

Cancers develop as a result of alteration in the genes that regulate growth, survival and other cellular behaviors. Tumor cells and DNA are shed into the lumen of colon. Uniquely mutated genes can be identified in the feces that would indicate the presence of a neoplasm (58). Stool based DNA testing is likely to be much better accepted by the public but the utility is yet to be studied (59).

**Wireless Capsule Endoscopy (WCE)**

(Walled Colon): A Promising Tool to Visualize the Colon

WCE to visualize the colon is in its early phase of investigation. It is likely that Pillcam colonoscopy may become an excellent alternative to colonoscopy which needs IV sedation. The elderly may be reluctant to undergo sedation and an invasive test associated with potentially life threatening complications. Initial studies on WCE have shown a good sensitivity to detect polyps. WCE has shown promise as a new technology for visualizing the colon in a serially blinded study; data was presented at the 2006 Annual American College of Gastroenterology meeting. Dr. Lewis reported that WCE might complement traditional colonoscopy in those unwilling to undergo standard colonoscopy. WCE was compared in a serially blinded study of 51 volunteers aged >50 years. WCE was reported to be more sensitive than VC in detecting small polyps (60).

The small chance of perforation and complications including those associated with IV sedation can be avoided with VC or Pillcam Colonoscopy (Pillcam colon). The group supportive of traditional colonoscopy as the sole procedure will argue that the use of the non-invasive studies such as VC or WCE when positive lead to traditional colonoscopy increasing the cost of health care. Certainly many older adults will prefer less invasive procedures and if found negative for polyps/cancer feel relieved that they do not require a tube test. The overall benefit will be that more geriatric patients would undergo CRC screening.

**THE CONTROVERSIES ON CRC IN THE ELDERLY**

A number of recent studies have raised questions on the value of screening for CRC in particular by
colonoscopy in the growing number of elderly after a certain age. The controversies relate to

1. the availability of resources,
2. the benefit of detecting a polyp or cancer in an advanced age with a limited life expectancy, and
3. the wisdom of subjecting a large number of elderly to a screening procedure that is potentially associated with complications, and many other minor issues (61–63).

Overall the decision to screen or not at any age is based on careful weighing of the benefits and risks of screening procedures, in particular colonoscopy. CRC screening even in the young with poor health and severe comorbidity is questioned (64). Obviously, in the elderly it is a major challenge to weigh the risks and benefits (65,66). Potential benefits of CRC screening decreases with age and multimorbidity as competing risks for mortality become more prominent. In their study Ko and Sonnenberg found that one cancer death would be prevented by screening 42 healthy men aged 70–74 years with colonoscopy, 178 healthy women aged 70–74 years with fecal occult blood tests, 431 women aged 75–79 years in poor health with colonoscopy, or 945 men aged 80–84 years in average health with fecal occult blood tests. The potential for screening-related complications was greater than estimated benefit in some population sub-groups aged 70 years and older. However at all ages, the potential reduction in mortality from screening outweighed the risk of colonoscopy-related death (67). Guidelines currently do not explain a maximum age beyond which screening is not endorsed (13,68).

In the debate on CRC screening in the elderly an issue that is often critically analyzed is the potential capacity that the health care system has in implementing screening to all. If our capacity is limited then there is a need to offer it to the most deserving population group that is expected to have a good life expectancy. In 2002 approximately 14.2 million colonoscopies were performed (46). There are currently 14.8 million people who are unscreened. There is insufficient capacity to serve the entire population with sigmoidoscopy and/or colonoscopy demanding substantial investment in space, equipment or personnel. It is reported that the demand for screening colonoscopy continues to strain the USA health care system despite the fact that the overall population sites participating in screening are low (10). In this context it is economically a worth while discussion to see whether CRC screening is being offered to population groups such as the very elderly with limited life expectancy.

In an excellent article Walter, et al have critically evaluated the value of colorectal, breast and cervical cancer in the elderly (61). Walter and Covinsky have developed a four point framework for evaluating screening CRC in an individual elderly patient, which nicely identifies the major issues to be recognized. The points include the following:

1. Estimation of life expectancy
2. the benefit of screening
3. the potential harm of screening
4. the value and preferences of the individual patient

Many of these points and others are discussed in many papers already quoted. We have discussed these and other points of interest in this raging debate (69).

Effect of Aging on the Incidence of CRC

While the incidence of CRC increases with age making screening a necessity, the competing risk of mortality from other causes is to be put into the equation in analyzing the cost-benefit ratio (70). Lin’s article carefully analyzed the issue. The prevalence of CRC was found to be 13.9% in patients aged 50–54 years, 26.7% in the age group 70–79 years and 28.2% in those 80 and above. Advanced neoplasia including high-grade neoplasia and cancer was found in 3.2%, 4.7%, and 14% of the cohorts aged 50–54 years, 75–79 years, and 80 years and above respectively. The mathematical modeling predicted that the mean extension of life expectancy was greater for those 50–54 years (0.85 years) than for older age groups (0.17 years and 0.13 years for those 75–79 years and those 80 and above) (71).

Although the incidence of CRC increases with advancing age, the risk of mortality from other causes increases simultaneously. The elderly patients 80 years and above gain only 15% of the expected benefit in life expectancy achieved by those aged 50–54 years. However, there is a persistent benefit among the very

(continued on page 33)
elderly although somewhat less than in the younger age groups (70).

The risk for neoplasia in one study was noted to decrease from 19% at age 65–69 to 14% after 70 years with the suggestion to stop CRC screening after age 70 (72). The latter study based on sigmoidoscopy can be challenged since age advanced right sided cancer is noted to increase.

Individuals who inherit mutations in MSH2 and MLH1 genes responsible for Hereditary Nonpolyposis Colon Cancer Syndrome (HNPCC) also show an age related increase in the risk for cancer. The risk for CRC progressively increases from >25% at the age of 50 years to almost 82% by the age of 70 (73,74). Hence there is no reason to believe that the incidence of CRC decreases after a certain age.

Do Comorbid Conditions Decrease the Life Expectancy Making the Benefit of Colon Cancer Screening Worthless?

As age advances obviously there is an accumulation of comorbid conditions which may shorten the life and may markedly negate any benefit that may result from CRC screening. The presence of multiple diseases in an elderly individual conceptualized recently as multimorbidity represents a paradigm shift from the term comorbidity. Multimorbidity (including cognitive impairment) is an important consideration for patients with CRC; the majority of them are aged 65 or older. A substantial proportion of deaths in older patients with CRC are attributable to CHF, Diabetes Mellitus, COPD, a few of the many multimorbidity conditions (75).

More than 90% of all the deaths in a study in a cohort of patients with stage 1 through stage 3 CRC were attributable to CHF, whereas 5% was attributable to COPD and almost 4% to diabetes. Because multimorbidity is so common, the view that many older persons may die with causes other than that from their cancer is to be reckoned with in prescribing screening colonoscopy (75).

What About the Cost of Screening Colonoscopy In a Population with a Shortened Life Expectancy?

Cost saving analysis of endoscopic CRC screening is not easy, and likely to be influenced by many factors in the elderly (82). Endoscopic CRC screening has the potential to be cost saving. Whether or not it continues to be cost saving as age advances needs to be determined. A case control study in which half the total number of patients was >70 years noted that those who died of CRC
were less likely to have had a colonoscopy in the prior ten years (OR = 0.43; 95% CI = 0.30 to 0.63) (7).

**Does CRC Respond Poorly to Chemotherapy in the Elderly?**

The behavior of CRC in the elderly was addressed by Sargent, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in older patients indicated that advancing age does not cause CRC to become more indolent or less responsive to surgery or chemotherapy (83) As in the younger individuals, localized CRC in older individuals responds well to treatment and is associated with less mortality and better survival than advanced disease (84).

**Other Issues**

Prior to 1998, Medicare did not routinely reimburse for colon cancer screening. The Consolidated Appropriations Act of 2001 extended the screening colonoscopy benefit to all individuals, regardless of risk beginning on July 1st, 2001 making colonoscopy affordable to the elderly (85). Although Medicare reimbursement of colonoscopy to the average risk population was implemented on 1st July, 2001 to reduce the economic access barrier to CRC screening, more than half of the elderly do not utilize the opportunity. It is likely that in certain segments of the society overpopulated by gastroenterologists there is a need to reduce misuse, but the data on a national scale indicates that our efforts should be to strengthen CRC screening and not dilute our efforts. CRC screening in the USA is utilized much less than that for breast or cervical cancers (86).

As Inadomi (70) has concluded commenting on Lin, et al’s article (71) that advocating a cut off age of 75 or 80 years may not be appropriate because there might be a persistent benefit derived from CRC screening even in the very old albeit less than the younger patients. Patient’s estimated life expectancy, personal preference, and societal resources which determine the analysis of cost-effectiveness, are all crucial factors in determining how far one should go into CRC screening. At this time little consensus has been reached with regards to a specific age beyond which CRC screening should be discontinued (70).

In summary CRC screening is useful in the geriatric population, but the decision to discontinue screening cannot be based on a guideline. CRC screening should be individualized based on quality of life of the patient, comorbid situations, and a rough estimate of the individual’s life expectancy. If risks outweigh the benefits, obviously screening for CRC by colonoscopy is not indicated. In the individual evaluation of an older adult for screening colonoscopy it is not enough to find out whether the patient can withstand the procedure, but serious consideration should be given to life expectancy, the effect of multimorbidity on the individual’s life and if necessary appropriate risk assessment based on ethnicity (87,88).

There are new technological advances in colonscopic techniques. Wireless capsule endoscopy is not yet available for colonoscopic examination in the USA, but is likely to be more acceptable than traditional colonoscopy. Virtual colonoscopy is likely to gain popularity. Chromo endoscopy and narrow band imaging (NBI) are not yet recommended for mass screening. Until a new technique excels traditional colonoscopy in detecting polyps, traditional colonoscopy is the choice.

**References**

17. Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with success rate and diagnostic yield. Gastrointest Endosc, 2004;60:408-413.